Genetics startup 23andMe announced significant changes, including halting the development of new medicines, laying off 40% of its workforce, and focusing on selling genetic tests to consumers for research. The company decided to close its therapeutics division and lay off 200 employees, ending a decade-long bet to become a drug company using genetic data. The CEO, Anne Wojcicki, expressed gratitude to the team and emphasized the commitment to supporting impacted employees during the transition. These restructuring actions are aimed at ensuring the long-term success of the core consumer business and research partnerships at 23andMe.
Source link
The end of 23andMe’s drug discovery dream
